← Leaderboards
James R Cerhan
Mayo Clinic Coll Of Medicine, Rochester
$31,221,407
Attributed
$44,091,577
Total exposure
16
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$48,491,574 · 17
By mechanism
U01$22,101,202 · 1
R01$15,608,188 · 5
P50$5,165,962 · 4
U54$4,399,997 · 1
P30$520,999 · 1
UH2$368,631 · 1
Top collaborators
- Christopher R Flowers19 shared
- Anne Josephine Novak5 shared
- Lisa Rimsza2 shared
- Yvonne L Kapila1 shared
- Clara M Lajonchere1 shared
- Janice S Lee1 shared
- Joseph Frank Petrosino1 shared
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Thomas E. Witzig$5,636,824
- Stephen M Ansell$7,057,055
Others in their field
Top investigators on “S Lymphoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$171,980,034
- Richard L Schilsky · University Of Chicago$120,036,663
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$113,682,224
- Ronald T Mitsuyasu · University Of California Los Angeles$103,553,444
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,393,123
- Charles A Coltman · Southwest Oncology Group$55,198,633
Research focus
S LymphomaNon-Hodgkin&AposGeneticResourcesMalignant NeoplasmsEpidemiologyLymphomaTumorClinicFollow-UpCohort StudiesDesignFundingSamplingMolecular EpidemiologyGrantDiagnosisInsightDisease ProgressionBaseSpecialized Program Of Research ExcellenceRisk StratificationEtiologyFollicular Lymphoma
Grant awards (81)
Human Virome Characterization Center for the Oral-Gut-Brain Axis$4,399,997
U54 · FY2025 · AG
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study$1,976,587
U01 · FY2025 · CA · contact PI
Assay Development and Prognostic Model for Predicting Early Clinical Failure in Follicular Lymphoma$161,663
UH2 · FY2025 · CA
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study$1,876,237
U01 · FY2024 · CA · contact PI
Assay Development and Prognostic Model for Predicting Early Clinical Failure in Follicular Lymphoma$206,968
UH2 · FY2024 · CA
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study (Diversity Supplement - Mazie Tsang)$127,071
U01 · FY2024 · CA · contact PI
Genetic Epidemiology and Risk Assessment Program$39,235
P30 · FY2024 · CA · contact PI
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study (Diversity Supplement - Alexis Romero)$20,848
U01 · FY2024 · CA · contact PI
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study$1,938,063
U01 · FY2023 · CA · contact PI
Genetic Epidemiology and Risk Assessment Program$99,154
P30 · FY2023 · CA · contact PI
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study$1,938,064
U01 · FY2022 · CA · contact PI
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study (Supplement)$195,572
U01 · FY2022 · CA · contact PI
Genetic Epidemiology and Risk Assessment Program$99,278
P30 · FY2022 · CA · contact PI
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study$2,008,420
U01 · FY2021 · CA · contact PI
Genetic Predictors of Early Clinical Failure in Diffuse Large B Cell Lymphoma$657,422
R01 · FY2021 · CA
Genetic Epidemiology and Risk Assessment Program$99,154
P30 · FY2021 · CA · contact PI
Genetic Epidemiology of non-Hodgkin Lymphoma$660,322
R01 · FY2020 · CA · contact PI
Genetic Predictors of Early Clinical Failure in Diffuse Large B Cell Lymphoma$657,422
R01 · FY2020 · CA
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study$486,178
U01 · FY2020 · CA · contact PI
Project 4: Genomic Predictors of Early Relapse in Immunochemotherapy-Treated Follicular Lymphoma$440,216
P50 · FY2020 · CA · contact PI
Genetic Epidemiology and Risk Assessment Program$101,597
P30 · FY2020 · CA · contact PI
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study$2,177,529
U01 · FY2019 · CA · contact PI
Genetic Epidemiology of non-Hodgkin Lymphoma$640,583
R01 · FY2019 · CA · contact PI
Genetic Predictors of Early Clinical Failure in Diffuse Large B Cell Lymphoma$637,699
R01 · FY2019 · CA
Project 4: Genomic Predictors of Early Relapse in Immunochemotherapy-Treated Follicular Lymphoma$445,888
P50 · FY2019 · CA · contact PI
Genetic Epidemiology and Risk Assessment Program$82,581
P30 · FY2019 · CA · contact PI
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study$67,878
U01 · FY2019 · CA · contact PI
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study$2,246,690
U01 · FY2018 · CA · contact PI
Genetic Epidemiology of non-Hodgkin Lymphoma$660,329
R01 · FY2018 · CA · contact PI
Genetic Predictors of Early Clinical Failure in Diffuse Large B Cell Lymphoma$650,403
R01 · FY2018 · CA
Project 4: Genomic Predictors of Early Relapse in Immunochemotherapy-Treated Follicular Lymphoma$460,809
P50 · FY2018 · CA · contact PI
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study$61,414
U01 · FY2018 · CA · contact PI
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study$2,248,270
U01 · FY2017 · CA · contact PI
Genetic Predictors of Early Clinical Failure in Diffuse Large B Cell Lymphoma$667,561
R01 · FY2017 · CA
Genetic Epidemiology of non-Hodgkin Lymphoma$662,837
R01 · FY2017 · CA · contact PI
Project 4: Genomic Predictors of Early Relapse in Immunochemotherapy-Treated Follicular Lymphoma$450,776
P50 · FY2017 · CA · contact PI
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study$14,960
U01 · FY2017 · CA · contact PI
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study$2,251,244
U01 · FY2016 · CA · contact PI
Genetic Epidemiology of non-Hodgkin Lymphoma$686,290
R01 · FY2016 · CA · contact PI
Genetic Epidemiology and Function of Germline and Somatic Variants in DLBCL$272,388
P50 · FY2016 · CA · contact PI
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study$45,332
U01 · FY2016 · CA · contact PI
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study$14,960
U01 · FY2016 · CA · contact PI
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study$2,405,885
U01 · FY2015 · CA · contact PI
Genetic Epidemiology and Function of Germline and Somatic Variants in DLBCL$268,695
P50 · FY2015 · CA · contact PI
Genetic Epidemiology and Function of Germline and Somatic Variants in DLBCL$272,471
P50 · FY2014 · CA · contact PI
Genetic Epidemiology and Function of Germline and Somatic Variants in DLBCL$268,944
P50 · FY2013 · CA · contact PI
Molecular Epidemiology of NHL and CLL$562,598
R01 · FY2012 · CA · contact PI
Genetic Epidemiology and Function of Germline and Somatic Variants in DLBCL$289,528
P50 · FY2012 · CA · contact PI
Genetic Epidemiology and Function of Germline and Somatic Variants in DLBCL$10,064
P50 · FY2012 · CA · contact PI
Molecular Epidemiology of NHL and CLL$584,461
R01 · FY2011 · CA · contact PI
P3 - Biology and Epidemiology of APRIL and Blys in B-cell and NHL$396,798
P50 · FY2011 · CA · contact PI
Molecular Epidemiology of NHL and CLL$626,174
R01 · FY2010 · CA · contact PI
Molecular Epidemiology of non-Hodgkin Lymphoma Survival$621,417
R01 · FY2010 · CA · contact PI
P3 - Biology and Epidemiology of APRIL and Blys in B-cell and NHL$425,497
P50 · FY2010 · CA · contact PI
Molecular Epidemiology of NHL and CLL$635,856
R01 · FY2009 · CA · contact PI
Molecular Epidemiology of non-Hodgkin Lymphoma Survival$609,140
R01 · FY2009 · CA · contact PI
Molecular Epidemiology of NHL and CLL$597,475
R01 · FY2009 · CA · contact PI
Biology and Epidemiology of APRIL and Blys in B-cell and NHL$425,295
P50 · FY2009 · CA · contact PI
Molecular Epidemiology of NHL and CLL$629,749
R01 · FY2008 · CA · contact PI
Biology and Epidemiology of APRIL and Blys in B-cell and NHL$373,113
P50 · FY2008 · CA · contact PI
Molecular Epidemiology of NHL and CLL$603,041
R01 · FY2007 · CA · contact PI
Biology and Epidemiology of APRIL and Blys in B-cell and NHL$365,480
P50 · FY2007 · CA · contact PI
Molecular Epidemiology of NHL and CLL$635,735
R01 · FY2006 · CA · contact PI
Immunogenetics of Non-Hodgkin Lymphoma Survival$223,318
R01 · FY2006 · CA · contact PI
Molecular Epidemiology of NHL and CLL$625,433
R01 · FY2005 · CA
Immunogenetics of Non-Hodgkin Lymphoma Survival$210,938
R01 · FY2005 · CA
FIRCA Breast Cancer Case-Control Study in Slovakia$34,560
R03 · FY2005 · TW
Molecular Epidemiology of NHL and CLL$592,731
R01 · FY2004 · CA
Immunogenetics of Non-Hodgkin Lymphoma Survival$212,062
R01 · FY2004 · CA
FIRCA Breast Cancer Case-Control Study in Slovakia$34,560
R03 · FY2004 · TW
Molecular Epidemiology of NHL and CLL$600,095
R01 · FY2003 · CA
Immunogenetics of Non-Hodgkin Lymphoma Survival$211,661
R01 · FY2003 · CA
FIRCA Breast Cancer Case-Control Study in Slovakia$34,560
R03 · FY2003 · TW
Immunogenetics of Non-Hodgkin Lymphoma Survival$245,436
R01 · FY2002 · CA
EPIDEMIOLOGIC FOLLOWUP OF THE BREAST CANCER FAMILY STUDY$0
P01 · FY2002 · CA
IMMUNOGENETICS OF NONHODGKIN LYMPHOMA SURVIVAL$0
P50 · FY2002 · CA
EPSTEIN-BARR VIRUS AND POSTMENOPAUSAL BREAST CANCER$62,725
R03 · FY2001 · CA
EPIDEMIOLOGIC FOLLOWUP OF THE BREAST CANCER FAMILY STUDY$0
P01 · FY2001 · CA
PRIOR BLOOD TRANSFUSION AS A CANCER RISK FACTOR$89,640
K07 · FY2000 · CA
EPSTEIN-BARR VIRUS AND POSTMENOPAUSAL BREAST CANCER$70,550
R03 · FY2000 · CA
EPIDEMIOLOGIC FOLLOWUP OF THE BREAST CANCER FAMILY STUDY$0
P01 · FY2000 · CA